Detalhe da pesquisa
1.
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Blood
; 143(14): 1399-1413, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194688
2.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Cancer
; 130(8): 1270-1280, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38153814
3.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Cancer
; 129(11): 1704-1713, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36932983
4.
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia.
Eur J Haematol
; 110(4): 354-361, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36480004
5.
Management of polycythemia vera: A survey of treatment patterns in Italy.
Eur J Haematol
; 110(2): 161-167, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36319575
6.
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis.
Cancer
; 128(13): 2449-2454, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35363892
7.
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study.
Br J Haematol
; 197(2): 190-200, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35137397
8.
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia.
Blood
; 136(2): 171-182, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32266380
9.
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study.
Blood
; 135(5): 381-386, 2020 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31869407
10.
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome.
Cancer
; 127(15): 2657-2665, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794557
11.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 193(2): 356-368, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222197
12.
Cytogenetic study in primary myelofibrosis at diagnosis: Clinical and histological association and impact on survival according to WHO 2017 classification in an Italian multicenter series.
Hematol Oncol
; 39(1): 123-128, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32979286
13.
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients.
Hematol Oncol
; 39(3): 409-418, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33590502
14.
Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
Ann Hematol
; 100(1): 105-116, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-33089365
15.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Cancer
; 126(6): 1243-1252, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31860137
16.
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Hematol Oncol
; 38(3): 372-380, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271957
17.
Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice.
Ann Hematol
; 99(1): 65-72, 2020 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-31832751
18.
Second cancers in MPN: Survival analysis from an international study.
Am J Hematol
; 95(3): 295-301, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31816122
19.
Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach.
Hematol Oncol
; 37(4): 424-433, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31359447
20.
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Hematol Oncol
; 37(3): 291-295, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31050810